Exeporfinium chloride (XF-73) nasal gel dosed over 24 hours prior to surgery significantly reduced Staphylococcus aureus nasal carriage in cardiac surgery patients: Safety and efficacy results from a randomized placebo-controlled phase 2 study.
| Autor: | Mangino JE; Division of Infection Diseases, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, United States., Firstenberg MS; William Novick Global Cardiac Alliance. Aurora, Colorado, United States., Milewski RKC; Department of Surgery, Yale School of Medicine, New Haven, Connecticut, United States., Rhys-Williams W; Destiny Pharma, Brighton, United Kingdom., Lees JP; Destiny Pharma, Brighton, United Kingdom., Dane A; Danestat Consulting Ltd, Macclesfield, United Kingdom., Love WG; Destiny Pharma, Brighton, United Kingdom., Gonzalez Moreno J; Destiny Pharma, Brighton, United Kingdom. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Infection control and hospital epidemiology [Infect Control Hosp Epidemiol] 2023 Jul; Vol. 44 (7), pp. 1171-1173. Date of Electronic Publication: 2023 Mar 23. |
| DOI: | 10.1017/ice.2023.17 |
| Abstrakt: | We studied 83 cardiac-surgery patients with nasal S. aureus carriage who received 4 intranasal administrations of XF-73 nasal gel or placebo <24 hours before surgery. One hour before surgery, patients exhibited a S. aureus nasal carriage reduction of 2.5 log |
| Databáze: | MEDLINE |
| Externí odkaz: |
|